ALX Oncology Holdings Inc.

    Jurisdiction
    United States
    ISIN
    US00166B1052 (ALXO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€103.76M
    EBIT margin
    0.0%
    Net income
    -€99.43M
    Net margin
    0.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Shantharam Harish Chief Financial Officer +75K $0.78 +$58.50K
    Lettmann Jason CHIEF EXECUTIVE OFFICER -2.4K $0.64 -$1.52K
    Pinto Shelly SVP, FINANCE AND CAO -611 $0.64 -$391.04

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 14K $8.91K -141K Sell

    Earnings Calls

    Add to watchlist

    Notifications